{"id":"https://openalex.org/W2189355406","doi":null,"title":"PreclinicalActivityoftheOralProteasomeInhibitorMLN9708 in Myeloma Bone Disease","display_name":"PreclinicalActivityoftheOralProteasomeInhibitorMLN9708 in Myeloma Bone Disease","publication_year":2014,"publication_date":"2014-01-01","ids":{"openalex":"https://openalex.org/W2189355406","mag":"2189355406"},"language":"en","primary_location":{"id":"mag:2189355406","doi":null,"is_oa":false,"landing_page_url":"https://clincancerres.aacrjournals.org/content/early/2014/02/26/1078-0432.CCR-13-1657.full.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null},"volume":null,"type":"article","is_traditional":true,"indexed_in":[],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5010026747","display_name":"Allison Berger","orcid":"https://orcid.org/0000-0003-1217-2005","observed_orcids":["https://orcid.org/0000-0003-1217-2005"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Allison Berger","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-1217-2005","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5051564773","display_name":"Carlos Ort\u00edz-de-Sol\u00f3rzano","orcid":"https://orcid.org/0000-0001-8720-0205","observed_orcids":["https://orcid.org/0000-0001-8720-0205"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Carlos Ort\u00edz-de-Sol\u00f3rzano","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0001-8720-0205","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5004781521","display_name":"Teresa Hern\u00e1ndez\u2010Iglesias","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Teresa Hern\u00e1ndez\u2010Iglesias","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5001224131","display_name":"Joaqu\u00edn Mateo-Urdiales","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Joaqu\u00edn Mateo-Urdiales","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071936150","display_name":"Susana Fraile","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Susana Fraile","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5008992375","display_name":"Miguel Galarraga","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Miguel Galarraga","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5006765393","display_name":"Dharminder Chauhan","orcid":"https://orcid.org/0000-0002-5548-6138","observed_orcids":["https://orcid.org/0000-0002-5548-6138"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Dharminder Chauhan","raw_affiliation_strings":[],"raw_orcid":null,"affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5020989412","display_name":"Jes\u00fas F. San Miguel","orcid":"https://orcid.org/0000-0002-9183-4857","observed_orcids":["https://orcid.org/0000-0002-9183-4857"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Jes\u00fas F. San Miguel","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0002-9183-4857","affiliations":[]},{"author_position":"middle","author":{"id":"https://openalex.org/A5052048627","display_name":"Noopur S Raje","orcid":"https://orcid.org/0000-0003-3066-1275","observed_orcids":["https://orcid.org/0000-0003-3066-1275"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Noopur Raje","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-3066-1275","affiliations":[]},{"author_position":"last","author":{"id":"https://openalex.org/A5018071694","display_name":"Mercedes Garayoa","orcid":"https://orcid.org/0000-0003-2194-2841","observed_orcids":["https://orcid.org/0000-0003-2194-2841"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mercedes Garayoa","raw_affiliation_strings":[],"raw_orcid":"https://orcid.org/0000-0003-2194-2841","affiliations":[]}],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":0.0,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":{"value":0.0,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":null,"issue":null,"first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9208999872207642,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10649","display_name":"Multiple Myeloma Research and Treatments","score":0.9208999872207642,"subfield":{"id":"https://openalex.org/subfields/2720","display_name":"Hematology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11219","display_name":"Bone Metabolism and Diseases","score":0.0608999989926815,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T11221","display_name":"Bone health and treatments","score":0.007600000128149986,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/ixazomib","display_name":"ixazomib","score":0.9779999852180481},{"id":"https://openalex.org/keywords/proteasome-inhibitors","display_name":"proteasome inhibitors","score":0.8050000071525574},{"id":"https://openalex.org/keywords/multiple-myeloma","display_name":"multiple myeloma","score":0.9629999995231628},{"id":"https://openalex.org/keywords/myeloma-bone-disease","display_name":"myeloma bone disease","score":0.9929999709129333},{"id":"https://openalex.org/keywords/osteoclastogenesis","display_name":"osteoclastogenesis","score":0.9449999928474426},{"id":"https://openalex.org/keywords/osteoclastic-bone-resorption","display_name":"osteoclast resorption","score":0.9430000185966492},{"id":"https://openalex.org/keywords/rankl","display_name":"RANKL","score":0.8299999833106995},{"id":"https://openalex.org/keywords/nf-kappab-signaling","display_name":"NF-\u03baB signaling","score":0.8790000081062317},{"id":"https://openalex.org/keywords/integrin-alphavbeta3","display_name":"integrin \u03b1v\u03b23","score":0.7879999876022339},{"id":"https://openalex.org/keywords/osteoblastogenesis","display_name":"osteoblastogenesis","score":0.9279999732971191},{"id":"https://openalex.org/keywords/osteoprogenitors","display_name":"osteoprogenitors","score":0.7360000014305115},{"id":"https://openalex.org/keywords/mesenchymal-stem-cells","display_name":"mesenchymal stem cells","score":0.8619999885559082},{"id":"https://openalex.org/keywords/bortezomib","display_name":"bortezomib","score":0.9229999780654907},{"id":"https://openalex.org/keywords/oral-administration","display_name":"oral administration","score":0.5979999899864197},{"id":"https://openalex.org/keywords/bone-resorption","display_name":"bone resorption","score":0.6209999918937683}],"concepts":[{"id":"https://openalex.org/C2776364478","wikidata":"https://www.wikidata.org/wiki/Q467635","display_name":"Multiple myeloma","level":2,"score":0.7242046594619751},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7121261954307556},{"id":"https://openalex.org/C2779428903","wikidata":"https://www.wikidata.org/wiki/Q418934","display_name":"RANKL","level":4,"score":0.6943427324295044},{"id":"https://openalex.org/C2781098529","wikidata":"https://www.wikidata.org/wiki/Q20948663","display_name":"Ixazomib","level":5,"score":0.6754719614982605},{"id":"https://openalex.org/C2776033226","wikidata":"https://www.wikidata.org/wiki/Q828410","display_name":"Osteoclast","level":3,"score":0.6318774223327637},{"id":"https://openalex.org/C2778260815","wikidata":"https://www.wikidata.org/wiki/Q917177","display_name":"Osteoblast","level":3,"score":0.6257297992706299},{"id":"https://openalex.org/C2780007613","wikidata":"https://www.wikidata.org/wiki/Q546523","display_name":"Bone marrow","level":2,"score":0.6224904656410217},{"id":"https://openalex.org/C673006","wikidata":"https://www.wikidata.org/wiki/Q4941581","display_name":"Bone resorption","level":2,"score":0.5872003436088562},{"id":"https://openalex.org/C2777478702","wikidata":"https://www.wikidata.org/wiki/Q419319","display_name":"Bortezomib","level":3,"score":0.5785660743713379},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.5565878748893738},{"id":"https://openalex.org/C2776169692","wikidata":"https://www.wikidata.org/wiki/Q4941552","display_name":"Bone disease","level":3,"score":0.5371215343475342},{"id":"https://openalex.org/C170033053","wikidata":"https://www.wikidata.org/wiki/Q952019","display_name":"Bone remodeling","level":2,"score":0.5028299689292908},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4577793478965759},{"id":"https://openalex.org/C134018914","wikidata":"https://www.wikidata.org/wiki/Q162606","display_name":"Endocrinology","level":1,"score":0.3413751423358917},{"id":"https://openalex.org/C2776541429","wikidata":"https://www.wikidata.org/wiki/Q165328","display_name":"Osteoporosis","level":2,"score":0.29920336604118347},{"id":"https://openalex.org/C88045685","wikidata":"https://www.wikidata.org/wiki/Q174576","display_name":"Activator (genetics)","level":3,"score":0.27302512526512146},{"id":"https://openalex.org/C202751555","wikidata":"https://www.wikidata.org/wiki/Q221681","display_name":"In vitro","level":2,"score":0.19547930359840393},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.15746113657951355},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.14264681935310364},{"id":"https://openalex.org/C2780108899","wikidata":"https://www.wikidata.org/wiki/Q15366934","display_name":"Carfilzomib","level":4,"score":0.12207451462745667},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"mag:2189355406","doi":null,"is_oa":false,"landing_page_url":"https://clincancerres.aacrjournals.org/content/early/2014/02/26/1078-0432.CCR-13-1657.full.pdf","pdf_url":null,"source":null,"license":null,"license_id":null,"version":null,"is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":null}],"best_oa_location":null,"sustainable_development_goals":[{"score":0.98580002784729,"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3"}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":42,"referenced_works":["https://openalex.org/W1842497498","https://openalex.org/W1964059429","https://openalex.org/W1964328292","https://openalex.org/W1966704794","https://openalex.org/W1969717239","https://openalex.org/W1988622995","https://openalex.org/W1992422220","https://openalex.org/W1995137745","https://openalex.org/W2001979983","https://openalex.org/W2003740173","https://openalex.org/W2010552629","https://openalex.org/W2016742872","https://openalex.org/W2025672294","https://openalex.org/W2031583115","https://openalex.org/W2033880166","https://openalex.org/W2035380808","https://openalex.org/W2038329170","https://openalex.org/W2041667009","https://openalex.org/W2043500890","https://openalex.org/W2065325944","https://openalex.org/W2067134630","https://openalex.org/W2074544136","https://openalex.org/W2086859574","https://openalex.org/W2091378741","https://openalex.org/W2097878023","https://openalex.org/W2101016269","https://openalex.org/W2106692847","https://openalex.org/W2109371953","https://openalex.org/W2119486128","https://openalex.org/W2122209792","https://openalex.org/W2126369996","https://openalex.org/W2135156120","https://openalex.org/W2135658123","https://openalex.org/W2135892640","https://openalex.org/W2145290116","https://openalex.org/W2149026101","https://openalex.org/W2154453937","https://openalex.org/W2155012110","https://openalex.org/W2155561150","https://openalex.org/W2167859307","https://openalex.org/W2554860654","https://openalex.org/W2979451615"],"related_works":["https://openalex.org/W2589353019","https://openalex.org/W2135658123","https://openalex.org/W2106692847","https://openalex.org/W2500802424","https://openalex.org/W2586323199","https://openalex.org/W4301326689","https://openalex.org/W2979876082","https://openalex.org/W2109371953","https://openalex.org/W2555052139","https://openalex.org/W2558803666"],"abstract_inverted_index":{"Purpose:":[0],"MLN9708":[1],"(ixazomib":[2],"citrate),":[3],"which":[4],"hydrolyzes":[5],"to":[6,78,167],"pharmacologically":[7],"active":[8],"MLN2238":[9,80,115,161],"(ixazomib),":[10],"is":[11],"a":[12,150,174],"next-generation":[13],"proteasome":[14],"inhibitor":[15],"with":[16,25,51,129,208],"demonstrated":[17],"preclinical":[18],"and":[19,49,53,82,86,105,121,138,171,186,196],"clinical":[20,198],"antimyeloma":[21,81,204],"activity,":[22],"but":[23],"yet":[24],"an":[26,69],"unknown":[27],"effect":[28],"on":[29,43,54,193],"myeloma":[30,77],"bone":[31,37,58,74,83,154,179,184],"disease.":[32],"Here,":[33],"we":[34],"investigated":[35],"its":[36,203],"anabolicandantiresorptiveeffectsinthemyelomasettingandincomparisonwithbortezomibinpreclinical":[38],"models.":[39],"Experimental":[40],"Design:Theinvitroeffectof":[41],"MLN2238wastested":[42],"osteoclastsandosteoclast":[44],"precursors":[45],"from":[46,57,64,127],"healthy":[47],"donors":[48],"patients":[50,128,207],"myeloma,":[52,158],"osteoprogenitors":[55,126],"derived":[56],"marrow":[59],"mesenchymal":[60],"stem":[61],"cells":[62],"also":[63,172],"both":[65,183],"origins.":[66],"We":[67],"used":[68],"in":[70,118,125,177,206],"vivo":[71],"model":[72,152],"of":[73,93,97,108,114,135,140,144,153,201],"marrow\u2013disseminated":[75,155],"human":[76,156],"evaluate":[79],"activities.":[84],"Results:ClinicallyachievableconcentrationsofMLN2238markedlyinhibitedinvitroosteoclastogenesis":[85],"osteoclast":[87],"resorption;":[88],"these":[89],"effects":[90],"involved":[91],"blockade":[92],"RANKL":[94],"(receptor":[95],"activator":[96],"NF-kB":[98,100],"ligand)induced":[99],"activation,":[101],"F-actin":[102],"ring":[103],"disruption,":[104],"diminished":[106],"expression":[107],"aVb3":[109],"integrin.":[110],"A":[111],"similar":[112],"range":[113],"concentrations":[116],"promoted":[117],"vitro":[119],"osteoblastogenesis":[120],"osteoblast":[122],"activity":[123,205],"(even":[124],"myeloma),":[130],"partly":[131],"mediated":[132],"by":[133,182],"activation":[134],"TCF/b-catenin":[136],"signaling":[137],"upregulation":[139],"the":[141,145],"IRE1":[142],"component":[143],"unfolded":[146],"protein":[147],"response.":[148],"In":[149],"mouse":[151],"multiple":[157],"orally":[159],"administered":[160],"was":[162],"equally":[163],"effective":[164],"as":[165],"bortezomib":[166],"control":[168],"tumor":[169],"burden":[170],"provided":[173],"marked":[175],"benefit":[176],"associated":[178],"disease":[180],"(sustained":[181],"anabolic":[185],"anticatabolic":[187],"activities).":[188],"Conclusion:":[189],"Given":[190],"favorable":[191],"data":[192],"pharmacologic":[194],"properties":[195],"emerging":[197],"safety":[199],"profile":[200],"MLN9708,itisconceivablethatthisproteasomeinhibitormayachievebonebeneficialeffectsinadditionto":[202],"myeloma.":[209],"Clin":[210],"Cancer":[211],"Res;":[212],"20(6);":[213],"1542\u201354.":[214],"\ufffd":[215],"2014":[216],"AACR.":[217]},"counts_by_year":[],"updated_date":"2026-09-22T06:50:58.402377","created_date":"2016-06-24T00:00:00"}